Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13093MR)

This product GTTS-WQ13093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13093MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12015MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ12499MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ4831MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ3684MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ1076MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ168MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ15447MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ542MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW